35% of patients with epithelial ovarian cancer may now be eligible for folate receptor alpha (FRa)- targeted therapy(1) VENTANA FOLR1 RxDx IHC Assay helps you find them.(2)

35% of patients with epithelial ovarian cancer may now be eligible for folate receptor alpha (FRα)- targeted therapy1

VENTANA FOLR1 RxDx IHC Assay helps you find them.2

Click to watch the digital slide review

Get your FREE Interpretation Guide
Download your PDF to learn about scoring, staining characteristics, and more. See below for additional details.

You're less than a minute away from your download. Please complete this form.

Help find a new option that gives her another chance

Introducing the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay, the first FDA-approved immunohistochemistry companion diagnostic test that helps you detect the Folate Receptor (FOLR1) biomarker in patients with epithelial ovarian cancer (EOC).2 By testing for FR alpha expression, you can help identify 35% of patients with EOC that may benefit from a promising FR alpha-targeted therapy.1

As part of its ongoing commitment to cancer care, Roche is proud to offer this advanced diagnostic tool, giving labs a way to help meet a critical need of patients with EOC.

Roche has testing solutions where and when it matters

Intended Use2
VENTANA FOLR1 (FOLR1-2.1) RxDx Assay is a qualitative immunohistochemical assay using mouse monoclonal anti-FOLR1, clone FOLR1-2.1, intended for use in the assessment of folate receptor alpha (FOLR1) protein in formalin-fixed, paraffin-embedded epithelial ovarian, fallopian tube, or primary peritoneal cancer tissue specimens by light microscopy. This assay is for use with OptiView DAB IHC Detection Kit for staining on a BenchMark ULTRA instrument.

FOLR1 expression clinical cut-off is ≥ 75% viable tumor cells (TC) with membrane staining at moderate and/or strong intensity levels.

This assay is indicated as an aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer who may be eligible for treatment with ELAHERE (mirvetuximab soravtansine).

Test results of the VENTANA FOLR1 (FOLR1-2.1) RxDx Assay should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.

This product is intended for in vitro diagnostic (IVD) use.

Exhibits 98% moderate and strong membrane staining or ≥ 75% tumor cells membrane staining with complete circumferential pattern

To order the VENTANA FOLR1 IHC Assay or have a VENTANA FOLR1 IHC Assay performed, contact one of the following laboratories.

Caris Life Sciences

4610 South 44th Place,
Phoenix, AZ 85040

Phone: 602-464-7500


NeoGenomics Laboratories

31 Columbia Aliso Viejo, CA 92656

Phone: 866-776-5907, option 3


LMC Pathology Services

7455 W. Washington Avenue,
Suite 301, Las Vegas, NV 89128

Phone: 877-LMC-LABS
Phone: 702-732-3441
Fax: 702-732-2310



3 Forest Parkway
Shelton, CT 06484

Phone: 800-345-GENE (4363)
Fax: 888-287-8199


Download your guide to learn more about FOLR1

The VENTANA FOLR1 (FOLR1-2.1) RxDx Assay Interpretation Guide offers valuable information to pathologists in the appropriate use of this product.
Your guide provides:

Scoring information

  • Learn about the clinical evaluation of sections stained with the VENTANA FOLR1 Assay using the appropriate scoring method
  • Find reference information for relating staining patterns and intensities to specific FOLR1 scores

Staining characteristics

  • See the difference between staining patterns that may result from staining of ovarian carcinoma tissues with the VENTANA FOLR1 Assay*
  • Explore images of challenging cases to provide guidance in their evaluation

Additional guidance

  • Discover how to use the FOLR1-positive control tissue when stained with the VENTANA FOLR1 Assay
  • Find various reference materials on stain intensity, specimen flow, and decision-making based on slides stained with the VENTANA FOLR1 Assay

*Images of primary peritoneal and primary fallopian tube cancer are not included in visual illustrations due to the rarity of these indications.